JP2009528838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528838A5 JP2009528838A5 JP2008558238A JP2008558238A JP2009528838A5 JP 2009528838 A5 JP2009528838 A5 JP 2009528838A5 JP 2008558238 A JP2008558238 A JP 2008558238A JP 2008558238 A JP2008558238 A JP 2008558238A JP 2009528838 A5 JP2009528838 A5 JP 2009528838A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human embryonic
- embryonic stem
- sample
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 15
- 108090001123 antibodies Proteins 0.000 claims 15
- 210000001671 Embryonic Stem Cells Anatomy 0.000 claims 13
- 210000004027 cells Anatomy 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 102100004162 PODXL Human genes 0.000 claims 3
- 101700030075 PODXL Proteins 0.000 claims 3
- 239000002771 cell marker Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 210000001161 Embryo, Mammalian Anatomy 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001809 detectable Effects 0.000 claims 1
- 101700069986 mab-5 Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (21)
- アミノ酸配列i)からiii)、若しくはアミノ酸配列iv)からvi)、若しくはアミノ酸配列i)からvi)を有する、未分化型ヒト胚性幹細胞を破壊することができる抗ポドカリキシン様タンパク質(PODXL)抗体:
或いはその変異体であって、配列i)からv)の1つ又は複数における1個若しくは2個のアミノ酸が別のアミノ酸で置換されている変異体。
i) SASSSVNYMY (配列番号2)
ii) DTSNLAS (配列番号3)
iii) QQWSSYPYT (配列番号4)
iv) NYWMN (配列番号5)
v) EIRLKSNNYATHYAESVKG (配列番号6)
vi) ERA (配列番号7) - 以下のCDR:
CDR1: SASSSVNYMY (配列番号2)
CDR2: DTSNLAS (配列番号3)
CDR3: QQWSSYPYT (配列番号4)
を組み入れている少なくとも1個の軽鎖可変領域を有する、請求項1に記載の抗PODXL抗体。 - 図11(配列番号8)に記載のアミノ酸配列を含む少なくとも1個の軽鎖可変領域を有する、請求項2に記載の抗体。
- 以下のCDR:
CDR1: NYWMN (配列番号5)
CDR2: EIRLKSNNYATHYAESVKG (配列番号6)
CDR3: ERA (配列番号7)
を組み入れている少なくとも1個の重鎖可変領域を有する、請求項1に記載の抗体、
或いはその変異体であって、CDR1及びCDR2の1つ又は複数における1個若しくは2個若しくは3個のアミノ酸が別のアミノ酸で置換されている変異体。 - 図12(配列番号10)に記載のアミノ酸配列を含む少なくとも1個の重鎖可変領域を有する、請求項4に記載の抗体。
- 請求項2又は3に記載の少なくとも1個の軽鎖可変領域、及び請求項4又は5に記載の少なくとも1個の重鎖可変領域を有する、請求項1に記載の抗体。
- mAb84である、請求項1から6のいずれか一項に記載の抗体。
- 抗体mAb84。
- 検出可能な標識をさらに含む、請求項1から8のいずれか一項に記載の抗体。
- 細胞毒性部分をさらに含む、請求項1から9のいずれか一項に記載の抗体。
- 請求項1から10のいずれか一項に記載の抗体、又は抗体中に含まれるVH又はVL鎖を含む分子をコードするポリヌクレオチド。
- 請求項11に記載のポリヌクレオチドを含む宿主細胞。
- 請求項1から10のいずれか一項に記載の抗体、及び他のヒト胚性幹細胞マーカーを検出するさらなる作用物質を含むパーツのキット。
- 他のヒト胚性幹細胞マーカーが、Oct4、SSEA−4、Tra−1−60、Tra−1−81、及びGCTM−2のいずれかである、請求項13に記載のパーツのキット。
- 他のヒト胚性幹細胞マーカーが、mAb5、mAb8、mAb14、mAb63、mAb84、mAb85、mAb95、mAb375、mAb432、及びmAb529のいずれかをさらに含む、請求項13に記載のパーツのキット。
- 未分化型ヒト胚性幹細胞を含む試料中で未分化型ヒト胚性幹細胞を破壊する方法であって、該試料を請求項1から10のいずれか一項に記載の抗体と接触させるステップを含む方法。
- 前記試料がヒト胚由来の試料又はヒト胚組織である、請求項16に記載の方法。
- 前記試料がin vitroで培養した細胞の試料である、請求項16又は請求項17に記載の方法。
- 前記試料が、該試料中で未分化型ヒト胚性幹細胞が特定の細胞系譜に分化するように促されている試料であり、かつ、前記試料が未分化型ヒト胚性幹細胞に由来する分化型細胞を含む、請求項16又は請求項17に記載の方法。
- 未分化型ヒト胚性幹細胞を含むin vitro試料中で未分化型ヒト胚性幹細胞を破壊するための、mAb84の使用。
- 分化型細胞を含むが未分化型ヒト胚性幹細胞が枯渇している薬剤組成物を作製する方法であって、
分化型細胞と未分化型ヒト胚性幹細胞とを含む試料を請求項1から10のいずれか一項に記載の抗体と接触させて、実質的に未分化型ヒト胚性幹細胞を含まない組成物を得るステップと、
さらに、前記組成物を薬剤組成物中に組み入れるステップと、を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77891306P | 2006-03-06 | 2006-03-06 | |
US60/778,913 | 2006-03-06 | ||
PCT/SG2007/000064 WO2007102787A1 (en) | 2006-03-06 | 2007-03-06 | Human embryonic stem cell methods and podxl expression |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009528838A JP2009528838A (ja) | 2009-08-13 |
JP2009528838A5 true JP2009528838A5 (ja) | 2010-04-22 |
JP5507086B2 JP5507086B2 (ja) | 2014-05-28 |
Family
ID=38475152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008558238A Expired - Fee Related JP5507086B2 (ja) | 2006-03-06 | 2007-03-06 | ヒト胚性幹細胞の方法及びpodxlの発現 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8173374B2 (ja) |
EP (2) | EP1994144B1 (ja) |
JP (1) | JP5507086B2 (ja) |
CN (1) | CN101454441B (ja) |
AU (1) | AU2007222165A1 (ja) |
CA (1) | CA2644856A1 (ja) |
IL (1) | IL193883A0 (ja) |
SG (1) | SG170065A1 (ja) |
WO (1) | WO2007102787A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173374B2 (en) | 2006-03-06 | 2012-05-08 | Agency For Science, Technology And Research | Human embryonic stem cell methods and PODXL expression |
WO2009108932A2 (en) * | 2008-02-28 | 2009-09-03 | The Johns Hopkins University | Selectin ligands useful in the diagnosis and treatment of cancer |
SG160248A1 (en) * | 2008-09-18 | 2010-04-29 | Agency Science Tech & Res | Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells |
EP2442106B1 (en) * | 2009-06-10 | 2015-08-19 | Masanori Hara | Method for test on diabetic nephropathy |
CN102803472B (zh) * | 2009-06-25 | 2014-04-23 | 吉隆公司 | 去除了外来表型的由多能干细胞分化的子代细胞 |
AU2010269451A1 (en) * | 2009-07-08 | 2012-02-02 | Actgen Inc. | Antibody having anti-cancer activity |
EP2473598B1 (en) | 2009-09-04 | 2017-03-22 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Methods for enhancing genome stability and telomere elongation in embryonic stem cells |
EP2315028A1 (en) | 2009-10-26 | 2011-04-27 | Atlas Antibodies AB | PODXL protein in colorectal cancer |
SG183171A1 (en) | 2010-02-04 | 2012-09-27 | Agency Science Tech & Res | Use of novel markers of pluripotent stem cells |
US8802376B2 (en) | 2010-07-21 | 2014-08-12 | Agency For Science, Technology And Research | Methods for identifying candidate cytotoxic antibody molecules |
US10000739B2 (en) | 2010-10-28 | 2018-06-19 | National University Corporation Kumamoto University | Method and culture medium for improving pluripotent stem cell differentiation inducing efficiency |
JP2014530201A (ja) * | 2011-09-20 | 2014-11-17 | イーライ リリー アンド カンパニー | 抗c−Met抗体 |
EP2746768A1 (en) * | 2012-12-20 | 2014-06-25 | Atlas Antibodies AB | Podxl in bladder cancer |
JP6742581B2 (ja) * | 2012-12-21 | 2020-08-19 | 学校法人立命館 | 標的細胞障害活性を有するiPS/ES細胞特異的抗体及びその用途 |
CN103204919B (zh) * | 2013-03-29 | 2014-10-08 | 浙江大学 | 胚胎干细胞特异性标志物Aire及其应用 |
CA2928043A1 (en) * | 2013-10-21 | 2015-04-30 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
US10428312B2 (en) | 2013-12-03 | 2019-10-01 | Agency For Science, Technology And Research | Cytotoxic antibody |
EP3095864B1 (en) | 2014-01-14 | 2020-04-15 | Kagoshima University | Method for labelling cancerization-causing cell in stem cells |
US20170335284A1 (en) * | 2014-11-07 | 2017-11-23 | Osaka University | Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same |
CA3000242A1 (en) * | 2015-10-01 | 2017-04-06 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
EP3604503A4 (en) * | 2017-03-28 | 2020-12-30 | Ajinomoto Co., Inc. | ADDITIVE FOR DE-DIFFERENTIATION SUPPORT MEDIUM |
CN113811601A (zh) * | 2018-12-26 | 2021-12-17 | 台湾地区“中央研究院” | 调节万能性干细胞的潜能的方法及应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
EP0699237B1 (en) * | 1994-03-17 | 2003-02-19 | MERCK PATENT GmbH | Anti-egfr single-chain fvs and anti-egfr antibodies |
GB9717946D0 (en) * | 1997-08-22 | 1997-10-29 | Imp Cancer Res Tech | Novel chemical entity |
AU2978899A (en) * | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
US7413904B2 (en) * | 1998-10-23 | 2008-08-19 | Geron Corporation | Human embryonic stem cells having genetic modifications |
WO2003046141A2 (en) * | 2001-11-26 | 2003-06-05 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
US20050281828A1 (en) | 2003-03-04 | 2005-12-22 | Bowdish Katherine S | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
US20030224411A1 (en) * | 2003-03-13 | 2003-12-04 | Stanton Lawrence W. | Genes that are up- or down-regulated during differentiation of human embryonic stem cells |
CA2568806C (en) * | 2003-06-09 | 2018-07-10 | The University Of British Columbia | Methods for detecting and treating cancer using podocalyxin and/or endoglycan |
US20080026460A1 (en) | 2006-06-20 | 2008-01-31 | Palecek Sean P | Method for culturing stem cells |
US20050233446A1 (en) | 2003-12-31 | 2005-10-20 | Parsons Xuejun H | Defined media for stem cell culture |
US20060182724A1 (en) * | 2005-02-15 | 2006-08-17 | Riordan Neil H | Method for expansion of stem cells |
BRPI0619794B8 (pt) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas |
US8173374B2 (en) * | 2006-03-06 | 2012-05-08 | Agency For Science, Technology And Research | Human embryonic stem cell methods and PODXL expression |
US20060294607A1 (en) | 2006-03-29 | 2006-12-28 | Applera Corporation | Human podocalyxin alternative-spliced forms and uses thereof |
US8968994B2 (en) | 2006-07-06 | 2015-03-03 | Jeremy Micah Crook | Method for stem cell culture and cells derived therefrom |
-
2007
- 2007-03-06 US US12/282,164 patent/US8173374B2/en active Active
- 2007-03-06 JP JP2008558238A patent/JP5507086B2/ja not_active Expired - Fee Related
- 2007-03-06 EP EP07716153.7A patent/EP1994144B1/en not_active Not-in-force
- 2007-03-06 SG SG201101522-9A patent/SG170065A1/en unknown
- 2007-03-06 WO PCT/SG2007/000064 patent/WO2007102787A1/en active Application Filing
- 2007-03-06 CN CN2007800082353A patent/CN101454441B/zh not_active Expired - Fee Related
- 2007-03-06 CA CA002644856A patent/CA2644856A1/en not_active Abandoned
- 2007-03-06 AU AU2007222165A patent/AU2007222165A1/en not_active Abandoned
- 2007-03-06 EP EP17188594.0A patent/EP3275901B1/en active Active
-
2008
- 2008-09-03 IL IL193883A patent/IL193883A0/en unknown
-
2012
- 2012-04-12 US US13/445,705 patent/US8710190B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009528838A5 (ja) | ||
HRP20210561T1 (hr) | Mjesta za vezanje antitijela specifičnih za egfrviii | |
Moschidou et al. | Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic acid acquire pluripotent characteristics | |
AR088455A1 (es) | Anticuerpos que antagonizan cd40l | |
RU2010133547A (ru) | Анти-cldn антитела | |
RU2019119442A (ru) | Новый коньюгат аманитина | |
JP2012520679A5 (ja) | ||
US20120128655A1 (en) | Induced pluripotent stem cells | |
RU2010116152A (ru) | Антитело против рецептора il-6 | |
PE20140218A1 (es) | Composicion farmaceutica | |
JP2008532523A5 (ja) | ||
HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
RU2013110875A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv | |
PE20100684A1 (es) | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh | |
Lu et al. | Engineering a functional three-dimensional human cardiac tissue model for drug toxicity screening | |
WO2015057545A3 (en) | Cysteine engineered fibronectin type iii domain binding molecules | |
JP2015527368A5 (ja) | ||
HRP20191729T1 (hr) | Novi spojevi i konjugati kriptoficina, njihova priprava i njihova terapeutska uporaba | |
JP2009505964A5 (ja) | ||
Wang et al. | Small quantum dots conjugated to nanobodies as immunofluorescence probes for nanometric microscopy | |
JP2016512214A5 (ja) | ||
RU2010120714A (ru) | Новые противовирусные пептиды, которые предотвращают связывание вируса с dlc8 | |
JP2020537520A5 (ja) | ||
JP2013500718A (ja) | 細胞リプログラミングを特徴付けかつこれを使用する方法 | |
ES2897945T3 (es) | Procedimiento de generación, identificación y aislamiento de cardiomiocitos derivados de células madre pluripotentes humanas y subpopulaciones de cardiomiocitos |